Predicting iron absorption from an effervescent iron supplement in obese patients before and after Roux-en-Y gastric bypass: a preliminary study.
Bariatric Surgery
Hepcidin
Iron Deficiency
Obesity
Oral Iron Absorption
Roux-en-Y Gastric Bypass
Journal
Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)
ISSN: 1878-3252
Titre abrégé: J Trace Elem Med Biol
Pays: Germany
ID NLM: 9508274
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
14
01
2018
revised:
03
12
2018
accepted:
05
12
2018
entrez:
9
2
2019
pubmed:
9
2
2019
medline:
25
6
2019
Statut:
ppublish
Résumé
Oral iron absorption is hampered in obese and bariatric patients, especially after Roux-en-Y gastric bypass (RYGB). As a result, iron deficiency, which is common in both patient groups, can be difficult to treat by oral supplements, often necessitating a switch to parenteral administration. The aim of this study was to find possible predictors of the extent of absorption of an effervescent iron gluconate oral supplement, which enables to pre-emptively identify those patients in which oral supplementation is likely to fail. The pharmacokinetic properties of 695 mg effervescent iron gluconate (80 mg Fe Low iron status persisted after surgery as there was no significant difference observed in TSAT (17.3 ± 5.2 vs. 20.2 ± 6.6%), ferritin (91.8 ± 68.6 vs. 136.2 ± 176.9 μg/L) and hepcidin concentration (32.0 ± 30.1 vs. 28.3 ± 21.3 ng/mL) after RYGB. The absorption of effervescent iron gluconate was similar pre- and post-RYGB [AUC The iron AUC
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Oral iron absorption is hampered in obese and bariatric patients, especially after Roux-en-Y gastric bypass (RYGB). As a result, iron deficiency, which is common in both patient groups, can be difficult to treat by oral supplements, often necessitating a switch to parenteral administration. The aim of this study was to find possible predictors of the extent of absorption of an effervescent iron gluconate oral supplement, which enables to pre-emptively identify those patients in which oral supplementation is likely to fail.
METHODS
METHODS
The pharmacokinetic properties of 695 mg effervescent iron gluconate (80 mg Fe
RESULTS
RESULTS
Low iron status persisted after surgery as there was no significant difference observed in TSAT (17.3 ± 5.2 vs. 20.2 ± 6.6%), ferritin (91.8 ± 68.6 vs. 136.2 ± 176.9 μg/L) and hepcidin concentration (32.0 ± 30.1 vs. 28.3 ± 21.3 ng/mL) after RYGB. The absorption of effervescent iron gluconate was similar pre- and post-RYGB [AUC
CONCLUSIONS
CONCLUSIONS
The iron AUC
Identifiants
pubmed: 30732902
pii: S0946-672X(18)30026-9
doi: 10.1016/j.jtemb.2018.12.002
pii:
doi:
Substances chimiques
Ferrous Compounds
0
Tablets
0
ferrous gluconate
U1B11I423Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
68-73Informations de copyright
Copyright © 2018 Elsevier GmbH. All rights reserved.